Clinical Review The American Journal of Gastroenterology (2006) 101, 2646–2654; doi:10.1111/j.1572-0241.2006.00844.x Proton Pump Inhibitor Therapy for Suspected GERD-Related Chronic Laryngitis: A Meta-Analysis of Randomized Controlled Trials Mohammed A Qadeer MD1, Christopher O Phillips MD, MPH2,3, A Rocio Lopez MS, MPH3, David L Steward MD4, J Pieter Noordzij MD5, John M Wo MD6, Maria Suurna MD4, Thomas Havas MD7, Colin W Howden MD8 and Michael F Vaezi MD, PhD, MSepi9 1Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio 2Department of General Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 3Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio 4Department of Otolaryngology, University of Cincinnati, Cincinnati, Ohio 5Department of Otolaryngology, Vanderbilt University, Nashville, Tennessee 6Department of Gastroenterology, University of Louisville, Louisville, Kentucky 7Department of Otolaryngology Head and Neck Surgery, University of New South Wales, Sydney, Australia 8Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 9Department of Gastroenterology, Vanderbilt University, Nashville, Tennessee Correspondence: Michael F. Vaezi, MD, PhD, MSepi, Department of Gastroenterology, Vanderbilt University Medical Center, 1501 TVC, 1301-22nd Ave. South, Nashville, TN 37232–5280. Received 19 April 2006; Accepted 15 June 2006. Top of page Abstract OBJECTIVE: The role of proton pump inhibitors (PPIs) in suspected GERD-related chronic laryngitis (CL) is controversial. Hence, we performed a meta-analysis of the existing randomized controlled trials (RCTs) to evaluate the efficacy of PPIs in this disorder. METHODS: Data extracted from MEDLINE (1966 to August 2005), Cochrane Controlled Trials Register (1997 to August 2005), EMBASE (1980 to August 2005), ClinicalTrials.gov website, and meetings presentations (1999–2005). Published and unpublished randomized placebo-controlled trials of PPIs in suspected GERD-related CL were selected by consensus. Random effects model was utilized with standard approaches to quality assessment, sensitivity analysis, and an exploration of heterogeneity and publication bias. The primary outcome measure was defined as the proportion of patients with greater than or equal to50% reduction in self-reported laryngeal symptoms. RESULTS: Pooled data from 8 studies (N = 344, PPI 195, placebo 149; mean age 51 yr; males 55%; study duration 8–16 wk) were analyzed. No significant quantitative heterogeneity was found among the studies (chi2 = 11.22, P = 0.13). Overall, PPI therapy resulted in a nonsignificant symptom reduction compared to placebo (relative risk 1.28, 95% confidence interval 0.94–1.74). No clinical predictors of PPI response were identified on meta-regression analysis done at study level. CONCLUSIONS: PPI therapy may offer a modest, but nonsignificant, clinical benefit over placebo in suspected GERD-related CL. Validated diagnostic guidelines may facilitate the recognition of those patients most likely to respond favorably to PPI treatment.
Posted on: Sat, 07 Sep 2013 02:06:48 +0000
Trending Topics
Recently Viewed Topics
© 2015